Analyst Price Targets — SGRY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 11, 2026 1:46 pm | — | US Capital Advisors | $21.00 | $13.50 | StreetInsider | UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders |
| March 4, 2026 5:12 pm | Brian Tanquilut | Jefferies | $16.25 | $14.27 | StreetInsider | Surgery Partners (SGRY) PT Lowered to $16.25 at Jefferies |
| March 4, 2026 1:04 pm | Ben Hendrix | RBC Capital | $20.00 | $14.22 | StreetInsider | Surgery Partners (SGRY) PT Lowered at RBC Capital as 2026 Guide Prompts Selloff |
| March 3, 2026 2:49 pm | — | Jefferies | $30.00 | $13.41 | StreetInsider | Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results |
| December 18, 2025 12:07 pm | — | Mizuho Securities | $19.00 | $15.80 | TheFly | Surgery Partners price target lowered to $19 from $22 at Mizuho |
| November 21, 2025 10:17 am | — | Barclays | $18.00 | $15.30 | TheFly | Surgery Partners price target lowered to $18 from $24 at Barclays |
| November 17, 2025 4:47 pm | — | Mizuho Securities | $22.00 | $15.20 | TheFly | Surgery Partners price target lowered to $22 from $28 at Mizuho |
| November 13, 2024 9:03 pm | Brian Tanquilut | Jefferies | $40.00 | $29.74 | StreetInsider | Surgery Partners (SGRY) PT Lowered to $40 at Jefferies |
| November 13, 2024 2:44 pm | Andrew Mok | Barclays | $31.00 | $29.74 | StreetInsider | Surgery Partners (SGRY) PT Lowered to $31 at Barclays |
| October 14, 2024 3:25 am | AJ Rice | UBS | $38.00 | $30.46 | StreetInsider | UBS Starts Surgery Partners (SGRY) at Buy |
Latest News for SGRY
Progyny (NASDAQ: PGNY - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current
Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations NEW YORK, April 1, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the…
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report)'s share price reached a new 52-week low during trading on Friday. The company traded as low as $11.53 and last traded at $11.6790, with a volume of 84480 shares traded. The stock had previously closed at $11.85. Analysts Set New Price Targets Several equities analysts have
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer 200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer
Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations NEW YORK, March 25, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SGRY.
U.S. House Trading
No House trades found for SGRY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.